ArticleBlood advances2022
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma.
Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01122472 (Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Covariate selection and adjustment for efficacy and safety endpoints in indirect comparative effectiveness analyses of CAR-T-cell therapies for large B-cell lymphoma: a systematic review.Journal of comparative effectiveness research · 2026Pooled it
- A convolutional neural network for fully automated total metabolic tumor volume delineation in patients with aggressive Non-Hodgkin lymphoma.European journal of nuclear medicine and molecular imaging · 2026Article
- Validation of an AI Method for Automated Lymphoma Metabolic Tumor Volume Segmentation Using a Public Benchmark PET/CT Dataset.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Clinical, Biological, and Treatment-Related Predictors of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis.European journal of nuclear medicine and molecular imaging · 2025Article
- Tumor metabolic heterogeneity based onBMC cancer · 2025Article
- Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2025Article
- Prognostic impact of metabolic tumor volume using the SUV4.0 segmentation threshold in 1,960 lymphoma patients from prospective LYSA trials.European journal of nuclear medicine and molecular imaging · 2025Article
- Prognostic Value of Multiple Manual Segmentation Methods for Diffuse Large B-Cell Lymphoma withCurrent oncology (Toronto, Ont.) · 2025Article
- Review
- Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience.Current oncology (Toronto, Ont.) · 2025Article
- Combining Total Metabolic Tumor Volume With Beta-2-Microglobulin Levels Predicts Outcomes in High-Burden Follicular Lymphoma Patients.Hematological oncology · 2025Article
- The Role of Artificial Intelligence and Radiomics in the Management of Lymphomas by PET/CT: The Clairvoyance in Clinic.Cancer management and research · 2025Review
- Clinical scoring systems, molecular subtypes and baseline [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- International Benchmark for Total Metabolic Tumor Volume Measurement in BaselineJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Prognostic value of the combination of volume, massiveness and fragmentation parameters measured on baseline FDG pet in high-burden follicular lymphoma.Scientific reports · 2024Article
- IsJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Tumor Location Relative to the Spleen Is a Prognostic Factor in Lymphoma Patients: A Demonstration from the REMARC Trial.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Quantitative PET-based biomarkers in lymphoma: getting ready for primetime.Nature reviews. Clinical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 15 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aggressive large B-cell lymphoma (LBCL) has variable outcomes. Current prognostic tools use factors for risk stratification that inadequately identify patients at high risk of refractory disease or relapse before initial treatment. A model associating 2 risk factors, total metabolic tumor volume (TMTV) >220 cm3 (determined by fluorine-18 fluorodeoxyglucose positron emission tomography coupled with computed tomography) and performance status (PS) ≥2, identified as prognostic in 301 older patients in the REMARC trial (#NCT01122472), was validated in 2174 patients of all ages treated in 2 clinical trials, PETAL (Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas; N = 510) and GOYA (N = 1315), and in real-world clinics (N = 349) across Europe and the United States. Three risk categories, low (no factors), intermediate (1 risk factor), and high (2 risk factors), significantly discriminated outcome in most of the series. Patients with 2 risk factors had worse outcomes than patients with no risk factors in the PETAL, GOYA, and real-world series. Patients with intermediate risk also had significantly worse outcomes than patients with no risk factors. The TMTV/Eastern Cooperative Oncology Group-PS combination outperformed the International Prognostic Index with a positive C-index for progression-free survival and overall survival in most series. The combination of high TMTV > 220 cm3 and ECOG-PS ≥ 2 is a simple clinical model to identify aggressive LBCL risk categories before treatment. This combination addresses the unmet need to better predict before treatment initiation for aggressive LBCL the patients likely to benefit the most or not at all from therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.